Chinese Systemic Lupus Erythematosus Treatment and Research Group (CSTAR) Registry XI: gender impact on long-term outcomes

Author:

Zhang S1ORCID,Ye Z2,Li C3,Li Z4,Li X5,Wu L6,Liu S7,Zuo X8,Zhu P9,Wang Z10,Wang Y11,Wang Z1ORCID,Zhao J1,Wang Q1,Tian X1,Li M1,Zeng X1

Affiliation:

1. Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China

2. Department of Rheumatology, The Fourth People's Hospital of Shenzhen Affiliated to Guangdong Medical College, Shenzhen, China

3. Department of Rheumatology, Beijing Children's Hospital Affiliated to Capital Medical University, Beijing, China

4. Department of Rheumatology, The Affiliated Hospital of Bengbu Medical College, Bengbu, China

5. Department of Rheumatology, Anhui Provincial Hospital, Hefei, China

6. Department of Rheumatology, The People's Hospital of Xinjiang Uygur Autonomous Region, Urumchi, China

7. Department of Rheumatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

8. Department of Rheumatology, Xiangya Hospital, Central South University, Changsha, China

9. Department of Rheumatology, Xijing Hospital affiliated to the Fourth Military Medical University, Xi'an, China

10. Department of Rheumatology, Beijing Tongren Hospital Affiliated to Capital Medical University, Beijing, China

11. Department of Epidemiology and Bio-statistics, Institute of Basic Medical Sciences, China Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Abstract

Objective The objective of this paper is to assess the role of gender on survival rate and causes of death and organ damage in systemic lupus erythematosus (SLE) patients in China from 2009 to 2015. Methods We conducted a multicenter cohort study to analyze the differences in outcome data between male and female SLE patients. A group of 1494 SLE patients who fulfilled the 1997 American College of Rheumatology SLE classification criteria were enrolled in the Chinese Systemic Lupus Erythematosus Treatment and Research Group (CSTAR) registry from April 2009 to February 2010. All enrolled patients were followed up at least once per year from 2009 to 2015. For patients who could not attend the outpatient clinic, follow-up was conducted by telephone interview. We collected demographic data, clinical manifestations and damage scores (System Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI)). Survival rates were evaluated using the Kaplan-Meier method. Results This study included 1352 women and 142 men. The five-year survival rates were 92.0% for men and 97.6% for women. The survival rates of males were significant lower than for females ( p = 0.019). Male patients received methylprednisolone pulse therapy and cyclophosphamide significantly more than female patients ( p = 0.010). During follow-up, 12 male patients and 66 female patients died. The most common cause of death was infection (41.7%) for men and active SLE disease (27.3%) for women. At the end of the study, the major accumulated organ damages included renal (8.5%) and musculoskeletal (7.7%), and nervous system (5.6%) for men and renal (8.8%) and musculoskeletal (6.7%) for women. There were no significant differences in SDI scores between the two groups at baseline and at the end of the study. Conclusions Male SLE patients had lower survival rates than female patients. Male patients received more methylprednisolone pulse and cyclophosphamide therapy. The most common causes of death were infection for male patients and active SLE disease for female patients. The major accumulated organ damages were renal, musculoskeletal, and nervous system both for male and female SLE patients in China.

Funder

Chinese National Key Technology R&D Program, Ministry of Science and Technology

Chinese National High Technology Research and Development Program, Ministry of Science and Technology

Publisher

SAGE Publications

Subject

Rheumatology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3